Status:
ACTIVE_NOT_RECRUITING
Cellular Senescence and COVID-19 Long-Hauler Syndrome
Lead Sponsor:
Mayo Clinic
Conditions:
SARS-CoV2 Infection
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to test if senescent cells and their secretome contribute to Long-Hauler Syndrome and if a clinical trial of senolytic drugs, which selectively eliminate senescent cells, ...
Eligibility Criteria
Inclusion
- Longhauler's Cohort -
- Ability to give informed consent or LAR.
- At least 18 years old.
- Ability of subject or LAR to read and speak the English language.
- Positive PCR or antibody test within 12 months of initial study visit.
- Patient of the Long-Hauler Syndrome clinic and differential diagnosis of Long-Hauler Syndrome.
Exclusion
- Any potential participant who refuses medical record review.
- Pregnant females.
- Incarcerated individuals.
- Inability to cooperate or any medical condition that, in the opinion of the investigator, interferes with the evaluation of the study objectives or increases the subject's risk by participating in the study.
- Control Cohort -
- Inclusion Criteria:
- Ability to give informed consent
- At least 18 years old
- Ability of subject to read and speak the English language
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04903132
Start Date
March 1 2021
End Date
December 1 2026
Last Update
June 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905